<DOC>
	<DOCNO>NCT01386606</DOCNO>
	<brief_summary>The study determine effect three dos Androxal ( enclomiphene citrate ) morning testosterone versus AndroGel ( approved topical treatment ) men low testosterone ( &lt; 350 ng/dL ) 6 week continuous dosing .</brief_summary>
	<brief_title>The Effect Androxal Versus Androgel Morning Testosterone Men With Secondary Hypogonadism ( Low Testosterone )</brief_title>
	<detailed_description>Study require 7 visit , include 2 overnight stay clinic . One visit eye exam . Blood sample require visit include sample every hour 24 hour time period 2 overnight stay . A six month extension study available subject complete 6-week study .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Enclomiphene</mesh_term>
	<mesh_term>Clomiphene</mesh_term>
	<mesh_term>Zuclomiphene</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Healthy male age 18 65 year age exhibit morning testosterone ≤350 ng/dL . All clinical laboratory test within normal range ( clinically significant deviation laboratory result require approval sponsor ) Ability complete study compliance protocol Ability understand provide write informed consent Agreement use condom , fertile female partner , another form contraception . Agreement provide semen sample clinic Use injectable , oral , topical , subcutaneous pelleted testosterone within 3 month prior study Use spironolactone , cimetidine , 5αreductase inhibitor , hCG , androgen , estrogen , anabolic steroid , DHEA , herbal hormone product study Use Clomid past year study Uncontrolled hypertension diabetes mellitus base Investigator 's assessment baseline . Subjects treat Type II diabetes exhibit glycemic control allow study . Newly diagnose diabetic need treat least 48 hour enrol study . A hematocrit ≥51 % hemoglobin ≥17 g/dL Clinically significant abnormal finding screen examination Use investigational drug product , participation drug medical device research study within 30 day prior receive study medication Known hypersensitivity Clomid Any condition opinion investigator would interfere participant 's ability provide inform consent , comply study instruction , possibly confound interpretation study result , endanger participant take part study Irreversibly infertile compromise fertility ( cryptorchism , Kallman Syndrome , primary hypogonadism , vasectomy , tumor pituitary ) History breast cancer History prostate cancer suspicion prostate disease unless rule prostate biopsy , PSA &gt; 3.6 History know hyperprolactinemia without tumor Chronic use medication use glucocorticoid Chronic use narcotic Subjects know positive HIV Subjects end stage renal disease Subjects cystic fibrosis ( mutation CFTR gene ) Subjects unable provide semen sample clinic Subject BMI &gt; 42 kg/m2</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>